linjc16/ctgov huggingface dataset:
Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia

Study Overview
=================
Brief Summary
-----------------
Despite advances in their classification and treatment, acute leukemia remain incurable disease for the majority of patients. It is necessary to identify new prognostic markers of survival and new therapeutic targets to improve prognosis. Some studies have shown that Fms-like tyrosine kinase 3-ligand (FLT3-L) could be interesting from this. A more recent study from our group testing a novel therapy in acute lymphoblastic leukemia, showed an increase of this marker in the blood of patients responding to treatment. The aim of our prospective, non-interventional study is to measure the plasma levels of FLT3-L at different times of the management of patients with acute lymphoblastic leukemia but also myeloid. For this, analyzes of the samples collected in the usual care will be conducted to study the relationship between the plasma concentration of FLT3-L and outcomes. If there is any link, the FLT3-L could serve as a predictor of treatment response.

Official Title
-----------------
Monocentric, Biological, Uncontrolled, Prospective Study on the Feasibility of Plasma FLT3 Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated With Intensively for Acute Leukemia

Conditions
-----------------
Acute Leukemia

Intervention / Treatment
-----------------
* Other: Non Interventional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute myelogenous leukemia diagnosis or lymphoblastic Patient intensively treated Patients who agreed to participate in the study and having signed the consent biocollection Non-Inclusion Criteria: Patient aged under 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dosage of plasma FLT3-L in adult patients with acute leukemia |  | up to three months |
Italian Network MDS Registry

Study Overview
=================
Brief Summary
-----------------
Epidemiological data collection of adult patients affected by myelodysplastic syndrome (MDS) newly diagnosed.

Detailed Description
-----------------
Development of an Italian regional registries MDS network using the same electronic case report form for data storage, with the following broad aims: Ability to aggregate and process anonymous epidemiological data collected by individual regional registers; Ability to aggregate the available data with those of other international registries existing.

Official Title
-----------------
Rete Italiana Dei Registri Regionali Delle Sindromi Mielodisplastiche (MDS)

Conditions
-----------------
Myelodysplastic-Myeloproliferative Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: New diagnosis of MDS Exclusion Criteria: Patient who refuse the signature of informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 106 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of MDS diagnosis | Number of new cases every 100.000 person/year | 6 years | 
| Overall Response rate | Proportion of CR or PR after each line of treatment in term of erythroid, platelet and granulocyte response | 6 years | 
| Prevalence of MDS | Number of cases every 100.000 person | 6 years | 
| Overall survival | Time between MDS diagnosis and death due to any causes | 6 years | 
| Progression free survival | Time between MDS diagnosis and relapse/ progression or death due to any causes | 6 years | 
| Progression to AML | Time between MDS diagnosis and Progression to AML or death due to any causes | 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MDS, Myelodisplastic Syndrome
Bronchial Obstruction in Dairy Farmers

Study Overview
=================
Brief Summary
-----------------
Chronic Obstructive Pulmonary Disease (COPD) is a major public health problem and is expected to become the 3rd leading cause of death globally by 2020. The main risk factor is tobacco. Tobacco poisoning is found in 80 to 90% of patients with COPD. However, non-smoking COPD is also described, with increasing prevalence figures, particularly related to occupational exposure, especially among farmers.

Detailed Description
-----------------
A prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6®) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany. The dairy farmers had an occupational medicine appointment and, if they demonstrated at least one marker of possible bronchial obstruction (chronic cough, chronic bronchitis, dyspnoea, wheezing, spirometry), they were referred to a pulmonologist.

Official Title
-----------------
Bronchial Obstruction in Dairy Farmers

Conditions
-----------------
COPD

Intervention / Treatment
-----------------
* Other: questionnaires and electronic mini-spirometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany control: non farmer Exclusion Criteria: pigs or grain farmers Pregnant women oral corticosteroids or immunosuppressive drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of bronchial obstruction | Respiratory specific indices are extracted from a screening spirometry : Forced expiratory volume in one second (FEV1) Forced Vital Capacity (FVC) Bronchial obstruction is stated with a ratio FEV1 / FVC < 0.8 | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of occupational specific COPD in dairy farmers | Occupational specific COPD is defined as a ratio FEV1 / FVC < 0.8 associated to a clinical situation : non reversibility after β2-agonists or corticoids administration, no personal nor familial allergic conditions, smoking history < 1 cigarettes package per year. | 3 years |
Can Neck Circumference Measurements Less Than 43cm or Greater Than 43cm Predict Difficulty of Tracheal Intubation?

Study Overview
=================
Brief Summary
-----------------
The circumference of a person's neck is a useful predictor of difficulty of insertion of a breathing tube.

Official Title
-----------------
Can Neck Circumference Measurements Less Than 43cm or Greater Than 43cm Predict Difficulty of Tracheal Intubation?

Conditions
-----------------
Neck Circumference, Difficulty of Tracheal Intubation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists physical status 1-4 Receiving general endotracheal anesthesia for surgery Exclusion Criteria: Limited range of motion of the neck or jaw Cervical spine injuries Upper airway pathology Previous facial trauma, or goiter Patients receiving regional anesthesia or anesthesia other than general, endotracheal anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Study Overview
=================
Brief Summary
-----------------
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.

Official Title
-----------------
Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Conditions
-----------------
Gastro-intestinal Stromal Tumours

Intervention / Treatment
-----------------
* Drug: oral masitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female patients, age >18 Life expectancy > 6 months Histological proven, metastatic, or locally advanced and non-operable, non- pre-treated GIST. Patients having never received any tyrosine kinase inhibitor, including as adjuvant therapy C-Kit (CD117) positive tumors detected immuno-histochemically Measurable tumor lesions with longest diameter >20 mm using conventional techniques or >10 mm with spiral CT scan Exclusion Criteria: Documented allergy to the similar drug of AB1010 Inadequate organ function Patients with a history of any other malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: masitinib (AB1010)<br>oral masitinib 7.5 mg/kg/day | Drug: oral masitinib<br>* 7.5 mg/kg/day<br>* Other names: AB1010;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST) |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival |  | until disease progression | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cKIT inhibitor, GIST
Non-small Cell Lung Cancer and Quality of Life

Study Overview
=================
Brief Summary
-----------------
The principal objective is to study clinical observations, symptoms and quality of life of non-small-cell lung cancer (NSCLC) patients undergoing specific non-operative treatment for cancer, including chemotherapy and radiotherapy.

Official Title
-----------------
Treatment of Non-small Cell Lung Cancer -Effects on Quality of Life and Symptom Control

Conditions
-----------------
Non Small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with verified NSCLC after the NSCLC diagnosis has been confirmed prior to first chemotherapy or radiotherapy Finnish speaking patients aged 18 years or more Written informed consent has to be signed Exclusion Criteria: Patients not consenting to participate in the study patients not able to communicate sufficiently cancer type is other than non-small-cell lung cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-small cell lung cancer patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of life, symptoms
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension

Study Overview
=================
Brief Summary
-----------------
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors. However, cirrhosis might be associated with upper gastrointestinal bleeding, particularly in case of portal hypertension or coagulopathy. This study aims to assess safety, efficacy and methods to prevent potential complications in cirrhosis or portal hypertension context for esophageal endoscopic resection. This retrospective multicentric French-Belgian study includes all consecutive patients with cirrhosis or portal hypertension who underwent esophageal endoscopic resection from January 2005 to 2021.

Official Title
-----------------
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension: a Multicenter Observational Study

Conditions
-----------------
Esophageal Neoplasms, Cirrhosis, Portal Hypertension

Intervention / Treatment
-----------------
* Procedure: Endosocpic resection of early esophageal tumor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 18 years with cirrhosis or portal hypertension who underwent endoscopic resection of an early esophageal tumor Exclusion Criteria: younger than 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cirrhotic patients or with portal hypertension<br>Patients with early esophageal cancer | Procedure: Endosocpic resection of early esophageal tumor<br>* under general anesthesia, by mucosectomy or endoscopic submucosal dissection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| technical success of early esophageal cancer resection | defined by a complete macroscopic resection | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse events per procedure (immediate bleeding, perforation) |  | baseline | 
| morbidity post procedure (delayed bleeding, infection, esophageal stenosis, 30-days related liver decompensation, 30-days related mortality) |  | up to 4 weeks | 
| Potential risk factors for adverse events |  | baseline | 
| preemptive methods to the risk of bleeding |  | baseline |
Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?

Study Overview
=================
Brief Summary
-----------------
OBJECTIVE: This study evaluated serum vascular endothelial growth factor (VEGF) concentrations in women with ectopic pregnancy (EP), abnormal intrauterine pregnancy (aIUP) and normal intrauterine pregnancy (nIUP). METHODS: This was a prospective, case-control study comparing serum VEGF concentrations among 72 women with ectopic pregnancy (n=35), abnormal IUP (n=15) and normal IUP (n=22) matched for gestational age. For the determination of serum VEGF concentration a solid phase sandwich ELISA was used. Patients were stratified according to serum VEGF above or below 200pg/mL. RESULTS: The serum level of VEGF was significantly higher in women with ectopic pregnancy (median 211.1 pg/mL; range 5 - 1017.0 pg/mL) than in women with normal IUP (median 5 pg/mL; range 5- 310.6 pg/mL) P < 0.0001. Serum VEGF concentrations did not show any statistically significant difference between women with aIUP (median 231.9 pg/mL range 5 - 813.7 pg /mL ) and EP (median 211.1 pg/mL range 5 - 1017.0 pg/mL). When cut-off concentrations of 200 pg/mL for VEGF were used, a nIUP could be distinguished from an unviable (EP and aIUP) with a sensitive of 53%, specificity of 90.9%, a positive predictive value of 92.9% and a negative predictive value of 46.5%.. CONCLUSIONS: Serum VEGF could not distinguish between an EP and an aIUP. However, serum VEGF concentrations above 200 pg/mL could discriminate a nIUP from an unviable pregnancy (EP or aIUP) with a PPV of 92.9%.

Official Title
-----------------
Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?

Conditions
-----------------
Ectopic Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:The inclusion criterion was the presence at transvaginal ultrasound of an extraovarian adnexal mass in women with a suspected ectopic pregnancy (amenorrhea, bleeding and pain) with positive test for beta-hCG. - Exclusion Criteria:The exclusion criterion was non-tubal ectopic pregnancy (cervical, cesarean scar, ovarian, and abdominal). -

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ectopic pregnancy, extra-uterine pregnancy<br>Ectopic pregnancy, control | |
| Abnormal intrauterine pregnancy<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study

Study Overview
=================
Brief Summary
-----------------
The diagnosis of Alzheimer's disease (AD) is based on clinical and neuropathological criteria. Some patients have a contributive CSF biology to determinate a high level risk of AD (Tau + phospho-tau ratio increased and Ab42 / decreased Aβ40), but others have an intermediate CSF biology (Tau and/or phospho-tau increased but Ab42 ratio / normal Aβ40) and are unclassifiable. 18F-Florbetaben (Neuraceq®), a radioisotope in positron emission tomography (PET), selectively binds to amyloid plaques, with high detection sensitivity (98%). Detection of amyloid plaques by PET imaging separate patients according to the criteria of Dubois, as with AD and allow them to benefit a cholinesterase inhibitor treatment. If negative, the diagnosis of AD can be excluded with a high level of confidence to prevent initiating unnecessary treatment, expensive for the community. This is the first imaging study of amyloid plaques targeting population whose diagnosis of AD is uncertain according to the CSF biology. The aim of this study is to describe the results of amyloid PET in case of intermediate CSF biology and to separate patients as AD or not according to the criteria of Dubois

Official Title
-----------------
18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study

Conditions
-----------------
Amyloid PET Imaging

Intervention / Treatment
-----------------
* Device: 18F-Florbetaben PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subjects who have given their consent to participate in the study. Patients with suspected AD and whose CSF markers give intermediate results (CSF punction less than 6 months): meaning tau and/or phospho-tau increased and Ab42 / Aβ40 normal (Ab42 / Aβ40 > 0.07). Non-indication to perform a PET 18F-Florbetaben. Affiliation to the french social security . Exclusion Criteria: Patients under guardianship. Inability to perform a PET 18F-Florbetaben (agitated patient, confused, ..). Pregnancy, lactation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FDG PET positive or negative<br> | Device: 18F-Florbetaben PET<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of positive or negative amyloid PET |  | 2 years |